Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 148 people enrolled
- Started
- 11 Nov 2020
- Ended
- 31 Aug 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sleep Fragmentation
- Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
- Sleep Continuity Disruption
- Undisturbed Sleep
- Record updated
- 24 September 2025
Who can take part
- Age
- 18 years to 48 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Healthy, 18-48 year olds meeting criteria for Normal Sleep
- Sleep phase within 21:00 and 08:00
- Total sleep time >6.5 and ≤8.5 hours/night; sleep efficiency ≥85%
- Non-smokers/nicotine users
- Low caffeine users (≤ 2 cups, q.d.)
- Life-time history of exposure to opioids, appropriately prescribed for pain
Who cannot take part
- Positive toxicology screen for opioids or recreational drugs
- Had exposure to ionizing radiation that in combination with the study's estimated radiation exposure would result in a cumulative exposure, exceeding recommended limits
- Lifetime history of chronic pain
- Meet clinical criteria for a sleep disorder
- Significant central nervous system disease (e.g., lupus, multiple sclerosis)
- Cognitive impairment, brain injury or history of closed head injury with loss of consciousness over 3 mins
- Other significant medical or psychiatric morbidity within 6 months or lifetime history of bipolar disorder, psychotic disorder, seizure disorder
- Any contraindicated medical condition
- Lifetime history of alcohol or substance used disorder
- Clinically significant abnormal complete blood count, hepatic, renal or metabolic panel
- BMI >35
- Acute pain
- Use in the last three months of the following: antidepressants, neuroleptics, sedative hypnotics, isoniazid, glucocorticoids, psychostimulants, opioids
- Pregnant or lactating women
- Significant preadmission psychological distress
- Embedded metal objects or fragments or electronic devices in the head or body that would present a risk during MRI
- Unable to tolerate the scanning environment/ claustrophobia
Where in United States
- Johns Hopkins School of MedicineBaltimore, United States
About the trial
What the trial wants to find out
The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) evaluate whether experimental SCD and/or SF alter resting or pain-evoked receptor binding potential in brain regions associated with pain inhibition; 2) examine whether SCD and/or SF alters the analgesic response and abuse liability profile of a study medication; and 3) determine whether receptor binding potentials in brain regions of interest are associated with study medication analgesia and abuse liability. The investigators will also evaluate the extent to which associations differ by sleep condition or sex.
The 3 groups in the trial
- Sleep Continuity DisruptionTreatment being tested
The Sleep Continuity Disruption condition will be conducted on two consecutive nights. An 8-hour sleep opportunity period will be disturbed by several forced awakenings at random intervals during which no sleep is permitted.
Treatment: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) and Sleep Continuity Disruption
- Sleep FragmentationTreatment being tested
The Sleep fragmentation condition will be conducted on two consecutive nights. Subjects are provided an 8-hour sleep opportunity during which their sleep will be disturbed by microarousals that simulate sleep apnea.
Treatment: Sleep Fragmentation and Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)
- Undisturbed SleepExisting treatment, for comparison
An 8-hour period of undisturbed sleep is permitted on each night.
Treatment: Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo) and Undisturbed Sleep
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Experimental Sleep Disruption and Fragmentation on Study Drug Receptor Function, Receptor Agonist Analgesia, and Abuse Liability
- Record updated
- 24 September 2025